Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel Controlled, Single-dose Phase I Clinical Study to Evaluate Pharmacokinetic Similarity, Safety, and Immunogenicity of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Parallel Controlled, Single-dose Phase I Clinical Study to Evaluate Pharmacokinetic Similarity, Safety, and Immunogenicity of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Colorectal cancer; Glioblastoma; Liver cancer; Non-small cell lung cancer
  • Focus Pharmacokinetics; Registrational
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 07 Jun 2022 Status changed from recruiting to completed.
    • 01 Oct 2021 According to a Coherus BioSciences media release, the company expects BLA filing in 2022.
    • 06 May 2021 According to a Coherus BioSciences media release, recruitment into this study has been slower than expected as a result of the COVID-19 pandemic, and Coherus now expects data from this study around year end 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top